Differences between genotype 1 patients with SVR or relapse after treatment for chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV)

被引：0
|
作者：
Zehnter, Elmar
Mauss, Stefan
Beoker, Klaus
Thomas, Lutz
Racky, Stefan
Schmidt, Wolfgang
Ullrich, Rainer
Sbrijer, Innessa
Heyne, Renate
Schober, Andreas
John, Christine
Hey, Karl-Heinz
Bokemeyer, Bernd
Kallinowski, Birgit
Moeller, Bernd
Pape, Stefan
Alshuth, Ulrich
Hueppe, Dietrich
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A789 / A789
页数：1
相关论文
共 50 条
  • [41] Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany -: A contribution to health care research
    Zehnter, E
    Mauss, S
    John, C
    Heyne, R
    Möller, B
    Bokemeyer, B
    Moog, G
    Alshuth, U
    Hüppe, D
    HEPATOLOGY, 2005, 42 (04) : 683A - 683A
  • [42] End of treatment and sustained response to peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (RBV) (COPEGUS) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC).
    Fargion, S
    Borzio, M
    Cargnel, A
    HEPATOLOGY, 2003, 38 (04) : 733A - 733A
  • [43] Predicitive Factors for Nonresponse in Genotype 2/3 Infected Chronic Hepatitis C (CHC) Patients Treated With Peginterferon Alfa-2A (PEG) and Ribavirin (RBV) in Real Life Setting
    Petersen, Joerg
    Lutz, Thomas
    Link, Ralph
    Moog, Gero
    Baumgarten, Axel
    Schott, Eckart
    Schmidt, Wolfgang
    Witthoeft, Thomas
    Schnaitmann, Eiko
    Seidel, Matthias
    Rieke, Ansgar P.
    Simon, Karl Georg
    Herrmann, Andreas
    Herold, Christoph
    Klass, Dietmar M.
    Alshuth, Ulrich
    Buggisch, Peter
    Mauss, Stefan
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2012, 142 (05) : S938 - S938
  • [44] PREDICTIVE FACTORS FOR NONRESPONSE IN GENOTYPE 2/3 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING
    Petersen, J.
    Lutz, T.
    Link, R.
    Moog, G.
    Baumgarten, A.
    Schott, E.
    Schmidt, W.
    Witthoeft, T.
    Schnaitmann, E.
    Seidel, M.
    Rieke, A.
    Simon, K. G.
    Herrmann, A.
    Herold, C.
    Klass, D.
    Alshuth, U.
    Buggisch, P.
    Mauss, S.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S454 - S454
  • [45] Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
    Jeffers, LJ
    Cassidy, W
    Howell, CD
    Hu, S
    Reddy, KR
    HEPATOLOGY, 2004, 39 (06) : 1702 - 1708
  • [46] Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
    Pijak, MR
    Gazdik, F
    Hrusovsky, S
    HEPATOLOGY, 2004, 40 (03) : 760 - 761
  • [47] Peginterferion alfa-2a (40KD) (Pegasys®) for the treatment of patients with chronic hepatitis C
    Ferenci, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (07) : 610 - 615
  • [48] POTENTIAL RELEVANCE OF VIRAL RESPONSE AT WEEK 8 AS A PREDICITIVE FACTOR FOR SVR IN GENOTYPE 1 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING
    Mauss, Stefan
    Boeker, Klaus
    Zehnter, Elmar
    Schober, Andreas
    Moog, Gero
    Lutz, Thomas
    Schuchmann, Marcus
    Heyne, Renate
    Schiffelholz, Willi
    John, Christine
    Hey, Karl-Heinz
    Baumgarten, Axel
    Geyer, Peter R.
    Pape, Stefan
    Lohmeyer, Juergen
    Schmidt, Wolfgang
    Alshuth, Ulrich
    Hueppe, Dietrich
    HEPATOLOGY, 2010, 52 (04) : 777A - 777A
  • [49] Peginterferon alfa-2a (40 KD) (pegasys) plus ribavirin (copegus) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis
    Marcellin, P
    Brillanti, S
    Cheinquer, H
    Cooksley, WGE
    Shiffman, L
    Schmidt, WE
    Brunda, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 154 - 154
  • [50] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
12345